Converting to Doxercalciferol Capsules From Intravenous Paricalcitol or Doxercalciferol

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages

  Kant, K Shashi ^a   Gonzalez, Alejandro R ^b   Hariachar, Srinivas ^c   Bernardo, Marializa ^d   Duggal, Ajay ^e   Engstrand, Sara ^e   Hunter, John ^e   Plone, Melissa ^e   Hertel, Joachim ^f  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Renal Endocrine Associates   (United States)

^c Outcomes Research International   (United States)

^d Southwest Houston Research Ltd   (United States)

^e GENZYME CORPORATION   (United States)

^f Nephrology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855196985     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.02.004     Document Type: Article

References (13)

1. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-S201. National Kidney Foundation.
2. Coburn J.W., Maung H.M., Elangovan L., et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004, 43:877-890.
3. 2) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000, 36:550-561.
4. 2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001, 37:532-543.
5. Hectorol Injection [package insert] 2008, Genzyme Corporation, Cambridge, MA.
6. Hectorol Capsules [package insert] 2009, Genzyme Corporation, Cambridge, MA.
7. Zemplar Capsules [package insert] 2009, Abbott Laboratories, North Chicago, IL.
8. Zemplar Injection [package insert] 2009, Abbott Laboratories, North Chicago, IL.
9. Zisman A.L., Ghantous W., Schinleber P., Roberts L., Sprague S.M. Inhibition of parathyroid hormone: a dose-equivalency study of paricalcitol to doxercalciferol. Am J Nephrol 2005, 25:591-595.
10. Fadem S., Al-Saghir F., Zollner G., Swan S. Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol-a dose equivalency and titration study. Clin Nephrol 2008, 70:319-324.
11. Upton R.A., Knutson J.C., Bishop C.W., LeVan L.W. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol Dial Transplant 2003, 18:750-758.
12. Tomasello S., Dhupar S., Sherman R.A. Phosphate binders, K/DOQI guidelines and compliance: the unfortunate reality. Dial Transplant 2004, 33:236-242.
13. Tentori F., Albert J.M., Eric W., et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009, 24:963-972.